Printer Friendly

ADVANCED TISSUE SCIENCES, INC. (FORMERLY MARROW-TECH INCORPORATED) FILES PUBLIC OFFERING OF 2,000,000 SHARES OF COMMON STOCK

ADVANCED TISSUE SCIENCES, INC. (FORMERLY MARROW-TECH INCORPORATED) FILES
 PUBLIC OFFERING OF 2,000,000 SHARES OF COMMON STOCK
 LA JOLLA, Calif., Dec. 24 /PRNewswire/ -- Advanced Tissue Sciences, Inc. (formerly Marrow-Tech Incorporated) (NASDAQ/NMS: ATISA) announced that it filed today with the Securities and Exchange Commission a registration statement covering the public offering of 2,000,000 shares of its common stock. The filing covers an additional 300,000 shares that will be subject to an option to cover over-allotments, if any. All of the shares to be offered will be issued and sold by Advanced Tissue Sciences and there will not be any selling stockholders.
 All of the shares will be offered by an underwriting group managed by Smith Barney, Upham Harris & Co. Incorporated and Montgomery Securities. A copy of the preliminary prospectus may be obtained from the office of Smith Barney, Upham Harris & Co. Incorporated, at 1345 Avenue of the Americas, 48th Floor, New York, N.Y. 10105 and Montgomery Securities at 600 Montgomery Street, San Francisco, Calif. 94111.
 The majority of the proceeds from the offering will be used to accelerate development of the company's skin related products and the research and development of therapeutic products incorporating other human tissue types. The balance of the net proceeds will be used to acquire capital equipment to support research and development and manufacturing, to fund sales and marketing programs, and for working capital and other general corporate purposes.
 Advanced Tissue Sciences is engaged in the growth of human tissues outside the body. The company is developing its proprietary three- dimensional cell culture system for potential therapeutic and laboratory applications.
 A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in the state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any such state.
 -0- 12/24/91
 /CONTACT: Gail K. Naughton, Ph.D., executive vice president and chief operating officer of Advanced Tissue Sciences, 619-450-5731/
 (ATISA) CO: Advanced Tissue Sciences, Inc. ST: California IN: MTC SU: OFR FC-OS -- SD001 -- 5144 12/24/91 11:29 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 24, 1991
Words:408
Previous Article:UNIQUEST ANNOUNCES SECOND QUARTER RESULTS
Next Article:GAS PRICE DOWN 26 CENTS FROM LAST CHRISTMAS, AAA REPORTS
Topics:


Related Articles
MARROW-TECH CHANGES NAME TO ADVANCED TISSUE SCIENCES
TOCOR II, INC. AND CENTOCOR, INC. INCREASE SIZE OF UNIT OFFERING
CHEMTRAK INCORPORATED FILES INITIAL PUBLIC OFFERING
TWO MILLION SHARES OF CALGENE COMMON STOCK OFFERED AT $11.25 PER SHARE
ADVANCED TISSUE SCIENCES ANNOUNCES LETTER OF INTENT TO ACQUIRE NEOMORPHICS INC.
THERATECH FILES INITIAL PUBLIC OFFERING OF 2,000,000 COMMON SHARES WITH SEC
ADVANCED TISSUE SCIENCES INC. REPORTS FIRST QUARTER RESULTS
ADVANCED TISSUE SCIENCES FILES TO EXPAND DERMAGRAFT(TM) CLINICAL TRIALS TO DIABETIC AND DECUBITUS ULCERS
ADVANCED TISSUE SCIENCES INC. ADOPTS STOCKHOLDER RIGHTS PLAN

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters